vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and UNIVERSAL DISPLAY CORP \PA\ (OLED). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $142.2M, roughly 1.2× UNIVERSAL DISPLAY CORP \PA\). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -14.5%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -5.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Universal Display Corporation is a developer and manufacturer of organic light emitting diode (OLED) technologies and materials, and it is a provider of services to the display and lighting industries.
ESPR vs OLED — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $142.2M |
| Net Profit | — | $35.9M |
| Gross Margin | — | 74.6% |
| Operating Margin | 50.6% | 30.1% |
| Net Margin | — | 25.2% |
| Revenue YoY | 143.7% | -14.5% |
| Net Profit YoY | — | -44.3% |
| EPS (diluted) | $0.32 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $142.2M | ||
| Q4 25 | $168.4M | $172.9M | ||
| Q3 25 | $87.3M | $139.6M | ||
| Q2 25 | $82.4M | $171.8M | ||
| Q1 25 | $65.0M | $166.3M | ||
| Q4 24 | $69.1M | $162.3M | ||
| Q3 24 | $51.6M | $161.6M | ||
| Q2 24 | $73.8M | $158.5M |
| Q1 26 | — | $35.9M | ||
| Q4 25 | — | $66.3M | ||
| Q3 25 | $-31.3M | $44.0M | ||
| Q2 25 | $-12.7M | $67.3M | ||
| Q1 25 | $-40.5M | $64.4M | ||
| Q4 24 | — | $46.0M | ||
| Q3 24 | $-29.5M | $66.9M | ||
| Q2 24 | $-61.9M | $52.3M |
| Q1 26 | — | 74.6% | ||
| Q4 25 | — | 76.1% | ||
| Q3 25 | — | 74.6% | ||
| Q2 25 | — | 77.2% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 77.0% | ||
| Q3 24 | — | 77.8% | ||
| Q2 24 | — | 75.8% |
| Q1 26 | — | 30.1% | ||
| Q4 25 | 50.6% | 38.9% | ||
| Q3 25 | -11.4% | 30.9% | ||
| Q2 25 | 8.6% | 39.9% | ||
| Q1 25 | -34.0% | 41.9% | ||
| Q4 24 | -6.4% | 32.3% | ||
| Q3 24 | -31.0% | 41.5% | ||
| Q2 24 | 3.5% | 35.6% |
| Q1 26 | — | 25.2% | ||
| Q4 25 | — | 38.4% | ||
| Q3 25 | -35.9% | 31.5% | ||
| Q2 25 | -15.4% | 39.2% | ||
| Q1 25 | -62.2% | 38.8% | ||
| Q4 24 | — | 28.4% | ||
| Q3 24 | -57.2% | 41.4% | ||
| Q2 24 | -83.9% | 33.0% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $0.32 | $1.40 | ||
| Q3 25 | $-0.16 | $0.92 | ||
| Q2 25 | $-0.06 | $1.41 | ||
| Q1 25 | $-0.21 | $1.35 | ||
| Q4 24 | $-0.14 | $0.96 | ||
| Q3 24 | $-0.15 | $1.40 | ||
| Q2 24 | $-0.33 | $1.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $516.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | — |
| Total Assets | $465.9M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $516.4M | ||
| Q4 25 | $167.9M | $602.4M | ||
| Q3 25 | $92.4M | $603.0M | ||
| Q2 25 | $86.1M | $525.2M | ||
| Q1 25 | $114.6M | $571.3M | ||
| Q4 24 | $144.8M | $492.7M | ||
| Q3 24 | $144.7M | $551.6M | ||
| Q2 24 | $189.3M | $530.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-302.0M | $1.8B | ||
| Q3 25 | $-451.4M | $1.7B | ||
| Q2 25 | $-433.5M | $1.7B | ||
| Q1 25 | $-426.2M | $1.7B | ||
| Q4 24 | $-388.7M | $1.6B | ||
| Q3 24 | $-370.2M | $1.6B | ||
| Q2 24 | $-344.2M | $1.5B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $465.9M | $2.0B | ||
| Q3 25 | $364.0M | $1.9B | ||
| Q2 25 | $347.1M | $1.9B | ||
| Q1 25 | $324.0M | $1.9B | ||
| Q4 24 | $343.8M | $1.8B | ||
| Q3 24 | $314.1M | $1.8B | ||
| Q2 24 | $352.3M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $108.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 3.03× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $108.9M | ||
| Q4 25 | $45.2M | $31.1M | ||
| Q3 25 | $-4.3M | $97.2M | ||
| Q2 25 | $-31.4M | $51.9M | ||
| Q1 25 | $-22.6M | $30.6M | ||
| Q4 24 | $-35.0M | $34.7M | ||
| Q3 24 | $-35.3M | $79.9M | ||
| Q2 24 | $-7.2M | $67.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $15.1M | ||
| Q3 25 | — | $84.3M | ||
| Q2 25 | — | $37.5M | ||
| Q1 25 | — | $17.5M | ||
| Q4 24 | — | $22.0M | ||
| Q3 24 | $-35.5M | $66.2M | ||
| Q2 24 | $-7.3M | $57.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 8.7% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 10.5% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | -68.7% | 41.0% | ||
| Q2 24 | -9.9% | 36.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 9.3% | ||
| Q3 25 | 0.0% | 9.2% | ||
| Q2 25 | 0.0% | 8.4% | ||
| Q1 25 | 0.0% | 7.9% | ||
| Q4 24 | 0.0% | 7.8% | ||
| Q3 24 | 0.3% | 8.4% | ||
| Q2 24 | 0.1% | 5.8% |
| Q1 26 | — | 3.03× | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 2.21× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | — | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OLED
| Material sales | $83.7M | 59% |
| Royalty and license fees | $54.2M | 38% |
| Contract research services | $4.3M | 3% |
